Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,281,797 papers from all fields of science
Search
Sign In
Create Free Account
pexelizumab
Known as:
h5G1.1-SC
, h5G1.1-scFv
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (2)
Antibodies, Monoclonal, Humanized
Single-Chain Antibodies
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Abstract 16645: Worse Renal Function is Associated with Markedly Worse Outcomes Among STEMI Patients Undergoing Primary PCI: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction…
J. Vavalle
,
S. Diepen
,
+8 authors
C. Granger
2012
Corpus ID: 74405627
2011
2011
Enhancement Cardiac Magnetic Resonance Substudy From the APEX-AMI Undergoing Primary Percutaneous Coronary Intervention: A Delayed Pexelizumab and Infarct Size in Patients With Acute Myocardial…
W. Hamm
,
P. Armstrong
,
+7 authors
E. Frank
2011
Corpus ID: 76761221
doi:10.1016/j.jcmg.2009.09.014 J. Am. Coll. Cardiol. Img. 2010;3;52-60 W. Hamm, Paul W. Armstrong, Christopher B. Granger, and…
Expand
2009
2009
VT/VF: a marker oF POST-PCI outcome
B. Mearns
Nature Reviews Cardiology
2009
Corpus ID: 43250377
limited information exists on whether ventricular tachycardia or fibrillation (Vt/VF) affects the prognosis of patients…
Expand
2007
2007
Pexelizumab and the APEX AMI trial. Authors' reply
P. Armstrong
,
C. Granger
,
J. Eikelboom
,
M. O’Donnell
2007
Corpus ID: 77778498
2007
2007
Patients transferred for primary PCI in APEX-AMI (Assessment of pexelizumab in acute myocardial infarction) trial have only modest symptom onset to PCI delays and good outcomes
P. Widimsky
,
W. Weaver
,
+7 authors
C. Granger
2007
Corpus ID: 78114146
2007
2007
Abstract 3216: The Serum of Pexelizumab-Treated ST-Segment Elevation MI Patients Reduces Complement Activation but not Cell Apoptosis
C. Martel
,
P. Théroux
,
+4 authors
P. Armstrong
2007
Corpus ID: 69099585
2006
2006
APEX Trial Results: Pexelizumab Shows No Effect on Mortality and Morbidity
T. O’Loughlin
,
P. Armstrong
2006
Corpus ID: 75731353
2004
2004
Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention…
J. Beranek
Circulation
2004
Corpus ID: 29470904
To the Editor: Mahaffey et al1 and Granger et al2 studied pexelizumab (Alexion Pharmaceuticals, Inc, Cheshire, Conn) as…
Expand
2004
2004
No Overall Benefit of Pexelizumab in CABG Patients
J. Foody
2004
Corpus ID: 78742059
The terminal complement inhibitor pexelizumab initially showed potential for limiting adverse cardiovascular events in patients…
Expand
2003
2003
Complement inhibitor cardioprotectant
L. Sorbera
,
J. Bozzo
,
M. Bayes
2003
Corpus ID: 79104852
Complement activation is greatly enhanced by several stimuli that take place during myocardial infarction and cardioputmonary…
Expand